IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-7.62%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$297M
AUM Growth
+$297M
(-9.6%)
Cap. Flow
-$15.4M
Cap. Flow
% of AUM
-5.17%
Top 10 Holdings %
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$8.41M |
| 2 |
uniQure
QURE
|
$8.23M |
| 3 |
Biogen
BIIB
|
$7.51M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$7.34M |
| 5 |
Gilead Sciences
GILD
|
$6.67M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.9M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$11.8M |
| 3 |
Amgen
AMGN
|
$10.2M |
| 4 |
Harmony Biosciences
HRMY
|
$8.39M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.93M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.8B
| $3.25M | 1.09% | 28,877 -40,000 | -58% | -$4.5M |
|
27
Sarepta Therapeutics
SRPT
$1.78B
| $3.23M | 1.09% | 26,700 +7,900 | +42% | +$957K |
|
28
Rocket Pharmaceuticals
RCKT
$354M
| $3.19M | 1.08% | 156,000 | – | – |
|
29
Denali Therapeutics
DNLI
$2.23B
| $3.17M | 1.07% | 154,000 -34,000 | -18% | -$700K |
|
30
AstraZeneca
AZN
$248B
| $3.15M | 1.06% | +46,500 | New | +$3.15M |
|
31
Xenon Pharmaceuticals
XENE
$2.98B
| $3.12M | 1.05% | 91,500 +66,000 | +259% | +$2.25M |
|
32
CRISPR Therapeutics
CRSP
$4.71B
| $2.86M | 0.96% | +63,000 | New | +$2.86M |
|
33
Madrigal Pharmaceuticals
MDGL
$9.76B
| $2.67M | 0.9% | 18,300 | – | – |
|
34
Legend Biotech
LEGN
$6.41B
| $2.55M | 0.86% | 38,000 | – | – |
|
35
Halozyme
HALO
$8.56B
| $2.38M | 0.8% | 62,200 -33,300 | -35% | -$1.27M |
|
|
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $2.34M | 0.79% | 290,000 +200,000 | +222% | +$1.61M |
|
|
ONC
37
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.28M | 0.77% | 12,700 +4,000 | +46% | +$719K |
|
38
Jazz Pharmaceuticals
JAZZ
$7.75B
| $2.23M | 0.75% | 17,200 | – | – |
|
39
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.13M | 0.72% | 67,500 | – | – |
|
40
Iovance Biotherapeutics
IOVA
$807M
| $2.02M | 0.68% | 445,000 +380,000 | +585% | +$1.73M |
|
41
Ionis Pharmaceuticals
IONS
$6.79B
| $1.95M | 0.66% | 43,000 | – | – |
|
42
Zai Lab
ZLAB
$3.68B
| $1.92M | 0.65% | 78,958 | – | – |
|
43
Genmab
GMAB
$15.3B
| $1.56M | 0.53% | +44,300 | New | +$1.56M |
|
44
Celldex Therapeutics
CLDX
$1.47B
| $1.32M | 0.45% | 48,099 | – | – |
|
45
Cogent Biosciences
COGT
$1.69B
| $1.31M | 0.44% | +135,000 | New | +$1.31M |
|
46
Dyne Therapeutics
DYN
$1.92B
| $1.23M | 0.41% | 137,751 -163,000 | -54% | -$1.46M |
|
47
NovoCure
NVCR
$1.38B
| $1.19M | 0.4% | 74,000 +42,000 | +131% | +$677K |
|
48
Amicus Therapeutics
FOLD
$2.34B
| $1.09M | 0.37% | +90,000 | New | +$1.09M |
|
49
Cytokinetics
CYTK
$4.23B
| $1.09M | 0.37% | 37,000 | – | – |
|
50
Guardant Health
GH
$8.41B
| $1.08M | 0.36% | 36,500 | – | – |
|